Close Menu

Patti Connolly, Paul Brenner

Feb 06, 2019

RenalytixAI has appointed Patti Connolly as its VP of clinical and scientific affairs. Connolly will lead the firm's recruitment efforts for the prospective clinical utility study for its KidneyIntelX assay, which the firm plans to begin in Q4 2019. Prior to RenalytixAI, Connolly served as clinical services director at Pearl Pathways.

RenalytixAI has also appointed and Paul Brenner to the firm's advisory board. Brenner currently serves as a computer science faculty member at the University of Notre Dame and associate director of Notre Dame's Center for Research Computing. Brenner also serves as a senior reserve advisor to the Air Force Cyber College Commandment.

More Like This

Jun 26, 2019

Christopher Bird

Christopher Bird has been appointed CMO of Danish IVD firm BioPorto, effective Aug. 1. He was previously at Roche Diagnostics where he headed the North American Medical and Scientific Affairs organization. At BioPorto, he will be responsible for building, executing, and overseeing the company's diagnostic product development strategy. 

Jun 25, 2019

Rupert Vessey

Bio-Techne appointed Rupert Vessey as an independent director to its board of directors, bringing the total number of board members to nine.

He is the president of global research and early development at Celgene. Before joining Celgene, Vessey held various R&D senior management positions at Merck. Previously, he worked in drug discovery, experimental medicine, and early clinical development at GlaxoSmithKline.

Jun 25, 2019

Eric Rasmussen, Bryan Baldasare

Meridian Bioscience has announced that Eric Rasmussen has resigned his position as executive vice president and CFO effective June 28, 2019 in order to pursue other opportunities. Meridian has appointed Bryan Baldasare, currently its senior vice president, corporate controller, treasurer, and chief accounting officer, to serve as interim CFO.

Jun 24, 2019

Patrick Balthrop

Oxford Immunotec Global has appointed Patrick Balthrop as chairman of its board of directors. Balthrop is chairman of the board of directors of Agendia and Discovery Life Sciences. He is also a member of the board of directors of Personalis and an executive advisor for Water Street Healthcare Partners. He served as president and CEO of Luminex from 2004 to 2014.

Richard Sandberg, the current chairman of Oxford Immunotec's board of directors, will remain a member of the board.

Jun 21, 2019

Puneet Sarin

BD has appointed Puneet Sarin the worldwide president of BD Biosciences. He will be responsible for driving the global strategic, operational, and commercial performance across BD Biosciences. Sarin was previously senior vice president and general manger of the chemistry and immunoassay business unit at Beckman Coulter. Prior to Beckman Coulter, he was at GE. 
Jun 21, 2019

Steven Daniel

Cofactor Genomics has appointed Steven Daniel as VP of business development. Daniel previously served as senior director of applied sciences and business development at ArcherDx. Prior to ArcherDx, he was VP of sales at Genos/Nantomics, senior director of pharma business development at Adaptive Biotechnologies, and held commercial roles at Life Technologies, AltheaDX, Metabolon, and Affymetrix.

Jun 19, 2019

Donald Berry

OTraces has announced that Donald Berry has joined its scientific advisory board. Berry is professor of biostatistics and founding chair of quantitative sciences at the University of Texas MD Anderson Cancer Center, bringing extensive cancer research and policy experience including work with the National Cancer Institute PDQ Screening and Prevention Committee. He has also worked closely with the FDA Center for Devices and Radiological Health, helping to set rigorous scientific and quality standards.

Jun 18, 2019

Maureen Cronin

Maureen Cronin has resigned from the board of Celcuity, the company said in a document filed with the US Securities and Exchange Commission. Cronin, who served as a directory since 2017, resigned on June 12. Her decision, Celcuity said, was not due to any disagreement with the company. 


Jun 17, 2019

Stefan Timmerman

Stefan Timmerman has been appointed CFO of Dutch transplantation and companion diagnostics firm Genome Diagnostics. Currently group controller of private equity firm Broadview Holding, Timmerman was previously controller at SNS bank. Before that, he held the same postition at ASN bank. 

Jun 14, 2019

Leena Das-Young

Guardant health said that Leena Das-Young is leaving her position as chief LUNAR officer and general manager at the company for personal reasons. She will continue her service with the firm through June 18, 2019. In connection with her departure, and in exchange for a customary release of claims, Das-Young will be entitled to certain benefits under the company’s executive severance plan, as well as the retention of certain relocation benefits previously provided to her.

Jun 11, 2019

Thomas Schinecker, Barbara Schädler, Michael Heuer, Stephan Feldhaus, Peter Voser

Thomas Schinecker has been appointed as CEO of Roche Diagnostics and a member of the firm's corporate executive committee, effective August 1. He will succeed Michael Heuer, who is retiring at the end of July. Schinecker is currently head of Centralized and Point of Care Solutions at Roche Diagnostics. Previously, he was general manager for Roche Diagnostics Germany, and before that, he held various management positions in marketing and sales as well as product development at Roche Diagnostics. He holds a PhD in molecular biology from New York University.

Barbara Schädler will become head of group communications and a member of Roche's enlarged Corporate Executive Committee, effective October 1. She will succeed Stephan Feldhaus, who will leave Roche at the end of September. Schädler is currently head of communications and public affairs at E.ON. Previously, she held communications manager positions at Lufthansa, SAP, and the German Federal Ministry of Finance. She holds a master's degree in economics from the University of Mainz.

Peter Voser will step down from the board of directors of Roche at the end of June due to his additional role as interim CEO of ABB.

Jun 11, 2019

Gail Marcus

Binx Health has appointed Gail Marcus to its board of directors. Marcus has held executive positions in a number of healthcare sectors, including services, diagnostics, healthcare provision, and managed care. She held leadership positions at United Healthcare, Cigna, and private equity-backed diagnostic organizations; has an academic appointment at Massachusetts College of Pharmacy and Health Sciences; and serves on the boards of Natera, Cambridge Epigenetix, and Triple S Management, a Blue Cross Blue Shield affiliate in Puerto Rico.

Jun 10, 2019

George Goedesky

George Goedesky has joined Affinity Biosensors as vice president of sales of marketing. He will lead the rollout of the LifeScale AST system for rapid antibiotic susceptibility tests. Most recently, Goedesky led the adoption of the Burker MALDII Biotyper platform in the Americas. The LifeScale AST platform is currently in US clinical trials for identifying targeted therapy for sepsis, Affinity Biosensors said. 

Jun 06, 2019

Eric d'Esparbes

Progenity has hired Eric d'Esparbes as its senior VP and CFO. Prior to Progenity, d'Esparbes served as CFO and interim principal executive officer at Innoviva. Before Innoviva, he held roles as CFO at Joule Unlimited, VP of finance at AEI, and CFO for Meiya Power Company. 

Jun 05, 2019

David King, Adam Schechter

David King is retiring from Laboratory Corporation of America as its president and CEO on Oct. 31 and will become its executive chairman of the board, effective Nov. 1, the company said this week. Adam Schechter will succeed King as president and CEO on that day.

King became CEO of LabCorp on Jan. 1, 2007. Prior to that he was the firm's executive vice president and COO, as well as its executive VP of strategic planning and corporate development. He joined the company as senior VP, general counsel, and chief compliance officer in 2001, and was LabCorp's principal outside legal counsel for several years before that.

The company noted that it has tripled in sized under King's leadership. It does business in more than 100 countries now, employs almost 61,000 employees, and recorded revenue of more than $11 billion in 2018.

Schechter is currently the lead independent director of LabCorp's board, which expects to choose another board member to be the lead independent director at a later date. Schechter, who has been a LabCorp director for six years, was formerly Merck executive vice president and president of global human health.